2017 International Congress

June 4-8, 2017. Vancouver, BC.

View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Personal KinetiGraph Devices Assessing Efficacy of Continuous Enteral Carbidopa/Levodopa Infusion Therapy

J. Margolesky, C. Luca (Miami, FL, USA)
PET-MRI Imaging in Parkinson Dementia Complex of Guam: A Case Report

A. Tran, K. Chan, V. Kharidi, E. Goldstein, R. Burns, P. Reyes (Phoenix, AZ, USA)
Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)

L. Adar, T. Rachmilewitz Minei, Y. Cohen, S. Oren (Rehovot, Israel)
Pharmacological modulation of mGluR5 improves dyskinesias mediated by D1 but not D2 receptor stimulation.

I. Sebastianutto, N. Maslava, L. Di Menna, F. Nicoletti, M. Cenci (Lund, Sweden)
Pharmaeconomic study of the treatment of advanced Parkinson’s disease.

F. VIVANCOS-MATELLANO, A. SANZ, J.U. MIRÓ, J. CADAVID, A. RUÍZ, N. SOLER (Madrid, Spain)
Phasic activity during non REM sleep

R. Miguel, I. Arnulf (Lisboa, Portugal)
Phenotype of PLP1-related disorder caused by novel mutation: a case report

N. Kresojevic, I. Petrovic, V. Dobricic, A. Tomic, M. Svetel, V. Kostic (Belgrade, Serbia)
Phenotypic Heterogeneity in PSP Variants – A Case Series

S. BHADRAN, S. ABRAHAM, B. NATARAJAN, A. MEKKATTUKUNNEL, J. KRISHNAN, R. ISAAC, P.K. PAL (THRISSUR, India)
Phosphodiesterases and striatal pathways in Parkinson’s disease

H. Wilson, G. Pagano, F. Niccolini, N. Muhlert, C. Coello, A. Tziortzi, G. Searle, R. Gunn, E. Rabiner, T. Foltynie, M. Politis (London, United Kingdom)
Physical Activity and Quality of Life in People with Parkinson’s Disease – A Long-term Follow-up Study

I-F. Shih, K. Paul, J. Bronstein, B. Ritz (Los Angeles, CA, USA)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z